Identification

Name
Indacaterol
Accession Number
DB05039
Type
Small Molecule
Groups
Approved
Description

Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.

Structure
Thumb
Synonyms
Not Available
External IDs
QAB 149 / QAB-149 / QAB149 / QVA-149 COMPONENT INDACATEROL
Product Ingredients
IngredientUNIICASInChI Key
Indacaterol maleate2JEC1ITX7R753498-25-8IREJFXIHXRZFER-PCBAQXHCSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arcapta NeohalerCapsule75 ug/1Oral; Respiratory (inhalation)Novartis2011-07-01Not applicableUs
Arcapta NeohalerCapsule75 ug/1Oral; Respiratory (inhalation)Sunovion2011-07-01Not applicableUs
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Limited2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Limited2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Limited2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Limited2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Limited2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Limited2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Limited2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Limited2009-11-30Not applicableEu
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ultibro BreezhalerIndacaterol (110 mcg) + Glycopyrronium (50 mcg)CapsuleRespiratory (inhalation)Novartis2014-03-05Not applicableCanada
Utibron NeohalerIndacaterol maleate (27.5 ug/1) + Glycopyrronium bromide (15.6 ug/1)CapsuleRespiratory (inhalation)Novartis2015-10-29Not applicableUs
Utibron NeohalerIndacaterol maleate (27.5 ug/1) + Glycopyrronium bromide (15.6 ug/1)CapsuleRespiratory (inhalation)Sunovion2017-04-03Not applicableUs
International/Other Brands
Arcapta (Novartis) / Hirobriz / Onbrez (Novartis) / Onbrize
Categories
UNII
8OR09251MQ
CAS number
312753-06-3
Weight
Average: 392.4907
Monoisotopic: 392.209992772
Chemical Formula
C24H28N2O3
InChI Key
QZZUEBNBZAPZLX-QFIPXVFZSA-N
InChI
InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
IUPAC Name
5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one
SMILES
CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1

Pharmacology

Indication

For the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Associated Conditions
Pharmacodynamics

Bronchodilator drugs are the foundation for the treatment of chronic obstructive pulmonary disease. The principal inhaled bronchodilator treatments used are β(2) -agonists and anticholinergics, either alone or in combination. Currently available β(2) -agonists are of either short duration and used multiple times/day, or of long duration, which requires twice-daily administration. Indacaterol is considered an ultra-long-acting β(2) -agonist and was recently approved for use in the United States. Its duration of action is approximately 24 hours, allowing for once-daily administration. Furthermore, this chiral compound it is given as the R-enantiomer and acts as a full agonist. Cough was the most commonly reported adverse effect with use of indacaterol. Compared to salmeterol, it has 35% more agonist activity. Cough usually occurred within 15 seconds of inhalation of the drug, lasted around 6 seconds, was not associated with bronchospasm, and did not cause discontinuation of the drug. Otherwise, the drug's safety profile was similar to that of other bronchodilators. [PMID: 22499359]

Mechanism of action

Indacaterol works by stimulating adrenergic beta-2 receptors in the smooth muscle of the airways. This causes relaxation of the muscle, thereby increasing the diameter of the airways, which become constricted in asthma and COPD. It is also long acting due to its high affinity to the lipid raft domains in the airway membrane so it slowly dissociates from the receptors. Indacaterol also has a high intrinsic efficacy so it is also very rapid acting - onset of action occurs within 5 minutes.

The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3-receptors. This selectivity profile is similar to formoterol. The clinical significance of these findings is unknown.

TargetActionsOrganism
ABeta-2 adrenergic receptor
agonist
Human
Absorption

The median time to reach peak serum concentrations of indacaterol was approximately 15 minutes after single or repeated inhaled doses. Absolute bioavailability of indacaterol after an inhaled dose was on average 43-45%.

Volume of distribution

After intravenous infusion the volume of distribution (Vz) of indacaterol was 2,361 L to 2,557 L indicating an extensive distribution.

Protein binding

The in vitro human serum and plasma protein binding was 94.1-95.3% and 95.1-96.2%, respectively.

Metabolism

After oral administration of radiolabeled indacaterol, unchanged indacaterol was the main component in serum, accounting for about one third of total drug-related AUC over 24 hours. The monohydroxylated derivative, glucuronide conjugate, and the 8-O-glucuronide were the most prominent metabolites in serum. Other metabolites identified include a diastereomer of the hydroxylated derivative, a N-glucuronide of indacaterol, and C- and N-dealkylated products.

In vitro investigations indicated that UGT1A1 was the only UGT isoform that metabolized indacaterol to the phenolic O-glucuronide. CYP3A4 is the predominant isoenzyme responsible for hydroxylation of indacaterol.

Route of elimination

Renal clearance plays a minor role (about 2 to 6% of systemic clearance) in the elimination of systemically available indacaterol. In a human ADME study where indacaterol was given orally, the fecal route of excretion was dominant over the urinary route. Indacaterol was excreted into human feces primarily as unchanged parent drug (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose).

Half life

Indacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing with once daily doses between 75 mcg and 600 mcg ranged from 40 to 56 hours which is consistent with the observed time-to-steady state of approximately 12-15 days.

Clearance

Renal clearance of indacaterol is, on average, between 0.46 and 1.2 L/h. Serum clearance of indacaterol is 18.8 L/h to 23.3 L/h.

Toxicity

The expected signs and symptoms associated with overdosage of indacaterol are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 bpm, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of indacaterol.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneIndacaterol may increase the hypokalemic activities of 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneIndacaterol may increase the hypokalemic activities of 19-norandrostenedione.Experimental, Illicit
5-androstenedioneIndacaterol may increase the hypokalemic activities of 5-androstenedione.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Indacaterol.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
AcepromazineAcepromazine may decrease the vasoconstricting activities of Indacaterol.Approved, Vet Approved
AcetaminophenThe serum concentration of Indacaterol can be increased when it is combined with Acetaminophen.Approved
Acetyl sulfisoxazoleThe metabolism of Indacaterol can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AlclometasoneIndacaterol may increase the hypokalemic activities of Alclometasone.Approved
AldosteroneIndacaterol may increase the hypokalemic activities of Aldosterone.Experimental, Investigational
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Indacaterol.Approved, Withdrawn
Ambroxol acefyllinateThe risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Indacaterol.Experimental, Investigational
AmcinonideIndacaterol may increase the hypokalemic activities of Amcinonide.Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Indacaterol.Illicit, Withdrawn
AminophyllineThe risk or severity of adverse effects can be increased when Aminophylline is combined with Indacaterol.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Indacaterol.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Indacaterol.Approved, Investigational
AmlodipineThe serum concentration of Indacaterol can be increased when it is combined with Amlodipine.Approved
AmoxapineThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Indacaterol.Approved, Illicit, Investigational
AnagrelideIndacaterol may increase the QTc-prolonging activities of Anagrelide.Approved
AndrostenedioneIndacaterol may increase the hypokalemic activities of Androstenedione.Experimental, Illicit
AnecortaveIndacaterol may increase the hypokalemic activities of Anecortave.Investigational
anecortave acetateIndacaterol may increase the hypokalemic activities of anecortave acetate.Investigational
ApalutamideThe serum concentration of Indacaterol can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Indacaterol can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
Arsenic trioxideIndacaterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherIndacaterol may increase the QTc-prolonging activities of Artemether.Approved
AsenapineIndacaterol may increase the QTc-prolonging activities of Asenapine.Approved
AtamestaneIndacaterol may increase the hypokalemic activities of Atamestane.Investigational
AtazanavirThe metabolism of Indacaterol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may decrease the bronchodilatory activities of Indacaterol.Approved
AtomoxetineAtomoxetine may increase the tachycardic activities of Indacaterol.Approved
AzithromycinIndacaterol may increase the QTc-prolonging activities of Azithromycin.Approved
AzosemideIndacaterol may increase the hypokalemic activities of Azosemide.Investigational
Beclomethasone dipropionateThe risk or severity of hypokalemia can be increased when Beclomethasone dipropionate is combined with Indacaterol.Approved, Investigational
BedaquilineIndacaterol may increase the QTc-prolonging activities of Bedaquiline.Approved
BendroflumethiazideIndacaterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Indacaterol.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Benzatropine.Approved
BenzthiazideIndacaterol may increase the hypokalemic activities of Benzthiazide.Approved
Benzyl alcoholThe serum concentration of Indacaterol can be increased when it is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineIndacaterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Bepridil.Approved, Withdrawn
BetamethasoneIndacaterol may increase the hypokalemic activities of Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
BevantololBevantolol may decrease the vasoconstricting activities of Indacaterol.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Indacaterol.Approved
BoceprevirThe metabolism of Indacaterol can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may decrease the bronchodilatory activities of Indacaterol.Approved
BortezomibThe metabolism of Indacaterol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Indacaterol can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleBrexpiprazole may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Indacaterol.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Indacaterol.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Brompheniramine.Approved
BucindololBucindolol may decrease the vasoconstricting activities of Indacaterol.Investigational
BudesonideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Indacaterol.Approved
BumetanideIndacaterol may increase the hypokalemic activities of Bumetanide.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Indacaterol.Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Indacaterol.Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Indacaterol.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Indacaterol.Approved
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Indacaterol.Approved
CarbamazepineThe serum concentration of Indacaterol can be decreased when it is combined with Carbamazepine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Indacaterol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Indacaterol.Approved
CarvedilolThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Carvedilol.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
CeritinibThe serum concentration of Indacaterol can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Cetirizine.Approved
ChloroquineIndacaterol may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideIndacaterol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Chlorphenamine.Approved
ChlorpromazineIndacaterol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneIndacaterol may increase the hypokalemic activities of Chlorthalidone.Approved
CiclesonideIndacaterol may increase the hypokalemic activities of Ciclesonide.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Ciprofloxacin.Approved, Investigational
CisaprideIndacaterol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramIndacaterol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Indacaterol can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Clemastine.Approved, Investigational
ClobetasolIndacaterol may increase the hypokalemic activities of Clobetasol.Approved, Investigational
Clobetasol propionateIndacaterol may increase the hypokalemic activities of Clobetasol propionate.Approved
ClobetasoneIndacaterol may increase the hypokalemic activities of Clobetasone.Approved
ClocortoloneIndacaterol may increase the hypokalemic activities of Clocortolone.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indacaterol.Approved, Investigational, Vet Approved
CloranololCloranolol may decrease the bronchodilatory activities of Indacaterol.Experimental
ClotrimazoleThe metabolism of Indacaterol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineIndacaterol may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Indacaterol can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Indacaterol.Approved, Investigational
Cortexolone 17α-propionateIndacaterol may increase the hypokalemic activities of Cortexolone 17α-propionate.Investigational
CorticosteroneIndacaterol may increase the hypokalemic activities of Corticosterone.Experimental
Cortisone acetateIndacaterol may increase the hypokalemic activities of Cortisone acetate.Approved, Investigational
CrizotinibThe metabolism of Indacaterol can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Indacaterol can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineThe risk or severity of hypertension can be increased when Cyclobenzaprine is combined with Indacaterol.Approved
CyclopenthiazideIndacaterol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Indacaterol can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapiprazoleDapiprazole may decrease the vasoconstricting activities of Indacaterol.Approved
DarunavirThe metabolism of Indacaterol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Indacaterol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Indacaterol can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortIndacaterol may increase the hypokalemic activities of Deflazacort.Approved, Investigational
DelavirdineThe metabolism of Indacaterol can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Indacaterol.Approved, Investigational
DesonideIndacaterol may increase the hypokalemic activities of Desonide.Approved, Investigational
DesoximetasoneIndacaterol may increase the hypokalemic activities of Desoximetasone.Approved
Desoxycorticosterone acetateIndacaterol may increase the hypokalemic activities of Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateIndacaterol may increase the hypokalemic activities of Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Indacaterol.Approved, Investigational
DexamethasoneThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Indacaterol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateIndacaterol may increase the hypokalemic activities of Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dexbrompheniramine.Approved
DexniguldipineThe serum concentration of Indacaterol can be increased when it is combined with Dexniguldipine.Experimental
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Indacaterol.Approved, Illicit
DexverapamilThe serum concentration of Indacaterol can be increased when it is combined with Dexverapamil.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Indacaterol.Experimental
DiflorasoneIndacaterol may increase the hypokalemic activities of Diflorasone.Approved
DifluocortoloneIndacaterol may increase the hypokalemic activities of Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateIndacaterol may increase the hypokalemic activities of Difluprednate.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Indacaterol.Approved, Investigational
DiltiazemThe metabolism of Indacaterol can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Indacaterol.Approved, Withdrawn
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Indacaterol.Approved, Investigational
DisopyramideIndacaterol may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideIndacaterol may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronIndacaterol may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneIndacaterol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Indacaterol.Approved
DoxazosinThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Indacaterol.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Doxofylline is combined with Indacaterol.Approved, Investigational
DoxycyclineThe metabolism of Indacaterol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Doxylamine.Approved, Vet Approved
DronedaroneIndacaterol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolIndacaterol may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Indacaterol.Approved
DyphyllineThe risk or severity of adverse effects can be increased when Dyphylline is combined with Indacaterol.Approved
EliglustatIndacaterol may increase the QTc-prolonging activities of Eliglustat.Approved
EmopamilThe serum concentration of Indacaterol can be increased when it is combined with Emopamil.Experimental
EnzalutamideThe serum concentration of Indacaterol can be decreased when it is combined with Enzalutamide.Approved
EpinephrineEpinephrine may decrease the vasoconstricting activities of Indacaterol.Approved, Vet Approved
EpitizideIndacaterol may increase the hypokalemic activities of Epitizide.Experimental
EquileninIndacaterol may increase the hypokalemic activities of Equilenin.Experimental
EquilinIndacaterol may increase the hypokalemic activities of Equilin.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Indacaterol.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Indacaterol.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Indacaterol.Approved
ErythromycinThe metabolism of Indacaterol can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramIndacaterol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Indacaterol.Approved
EstroneIndacaterol may increase the hypokalemic activities of Estrone.Approved
Estrone sulfateIndacaterol may increase the hypokalemic activities of Estrone sulfate.Approved
Etacrynic acidIndacaterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Indacaterol can be decreased when it is combined with Ethinyl Estradiol.Approved
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Indacaterol.Approved
FelodipineThe serum concentration of Indacaterol can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Indacaterol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FlecainideIndacaterol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluasteroneIndacaterol may increase the hypokalemic activities of Fluasterone.Investigational
FluconazoleThe metabolism of Indacaterol can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneIndacaterol may increase the hypokalemic activities of Fludrocortisone.Approved, Investigational
FlumethasoneIndacaterol may increase the hypokalemic activities of Flumethasone.Approved, Vet Approved
FlunisolideIndacaterol may increase the hypokalemic activities of Flunisolide.Approved, Investigational
Fluocinolone AcetonideIndacaterol may increase the hypokalemic activities of Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideIndacaterol may increase the hypokalemic activities of Fluocinonide.Approved, Investigational
FluocortoloneIndacaterol may increase the hypokalemic activities of Fluocortolone.Approved, Withdrawn
FluorometholoneIndacaterol may increase the hypokalemic activities of Fluorometholone.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolIndacaterol may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluprednideneIndacaterol may increase the hypokalemic activities of Fluprednidene.Approved, Withdrawn
FluprednisoloneIndacaterol may increase the hypokalemic activities of Fluprednisolone.Approved
FlurandrenolideIndacaterol may increase the hypokalemic activities of Flurandrenolide.Approved
FluticasoneIndacaterol may increase the hypokalemic activities of Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateIndacaterol may increase the hypokalemic activities of Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of hypokalemia can be increased when Fluticasone propionate is combined with Indacaterol.Approved
FluvoxamineThe serum concentration of Indacaterol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneIndacaterol may increase the hypokalemic activities of Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Indacaterol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Indacaterol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Indacaterol can be increased when combined with Fosphenytoin.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of hyperkalemia can be increased when Indacaterol is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Indacaterol can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadobenic acidIndacaterol may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GallopamilThe serum concentration of Indacaterol can be increased when it is combined with Gallopamil.Investigational
GanciclovirThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Indacaterol.Approved, Investigational
GemifloxacinIndacaterol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlyburideThe serum concentration of Indacaterol can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Indacaterol can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinIndacaterol may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronIndacaterol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HalcinonideIndacaterol may increase the hypokalemic activities of Halcinonide.Approved, Investigational, Withdrawn
HaloperidolIndacaterol may increase the QTc-prolonging activities of Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Indacaterol.Experimental
HE3286Indacaterol may increase the hypokalemic activities of HE3286.Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Indacaterol.Experimental
HydrochlorothiazideIndacaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Indacaterol.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of hypokalemia can be increased when Hydrocortisone acetate is combined with Indacaterol.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Indacaterol.Approved, Vet Approved
HydroflumethiazideIndacaterol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Indacaterol.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indacaterol.Approved, Investigational
IbuprofenThe serum concentration of Indacaterol can be increased when it is combined with Ibuprofen.Approved
IbutilideIndacaterol may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe metabolism of Indacaterol can be decreased when combined with Idelalisib.Approved
IloperidoneIndacaterol may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Indacaterol can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indacaterol.Approved
IndapamideIndacaterol may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Indacaterol can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Indacaterol.Withdrawn
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Indacaterol.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Indacaterol.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Indacaterol.Withdrawn
IsavuconazoleThe serum concentration of Indacaterol can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Indacaterol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Indacaterol.Approved
IsradipineThe serum concentration of Indacaterol can be increased when it is combined with Isradipine.Approved, Investigational
IstaroximeIndacaterol may increase the hypokalemic activities of Istaroxime.Investigational
ItraconazoleThe metabolism of Indacaterol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Indacaterol can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Indacaterol can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Labetalol.Approved
LamotrigineThe serum concentration of Indacaterol can be decreased when it is combined with Lamotrigine.Approved, Investigational
LenvatinibIndacaterol may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LeuprolideIndacaterol may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinIndacaterol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Indacaterol.Approved, Investigational
LidocaineThe serum concentration of Indacaterol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Indacaterol.Experimental
LomerizineThe serum concentration of Indacaterol can be increased when it is combined with Lomerizine.Experimental
LoperamideThe serum concentration of Indacaterol can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Indacaterol can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Indacaterol can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Indacaterol can be increased when it is combined with Losartan.Approved
LoteprednolIndacaterol may increase the hypokalemic activities of Loteprednol.Approved
LovastatinThe metabolism of Indacaterol can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Loxapine.Approved
LuliconazoleThe serum concentration of Indacaterol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Indacaterol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineIndacaterol may increase the QTc-prolonging activities of Lumefantrine.Approved
ME-609Indacaterol may increase the hypokalemic activities of ME-609.Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Indacaterol.Withdrawn
MedrysoneIndacaterol may increase the hypokalemic activities of Medrysone.Approved
MelengestrolIndacaterol may increase the hypokalemic activities of Melengestrol.Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Indacaterol.Experimental, Investigational
MepindololMepindolol may decrease the bronchodilatory activities of Indacaterol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Mepyramine.Approved, Vet Approved
MethadoneIndacaterol may increase the QTc-prolonging activities of Methadone.Approved
MethotrimeprazineMethotrimeprazine may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
MethyclothiazideIndacaterol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Indacaterol.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Indacaterol.Approved
MethylprednisoloneThe risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Indacaterol.Approved, Vet Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Indacaterol.Approved, Investigational
MetolazoneIndacaterol may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Metoprolol.Approved, Investigational
MibefradilThe metabolism of Indacaterol can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Indacaterol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Indacaterol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Indacaterol.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Indacaterol.Approved
MitotaneThe serum concentration of Indacaterol can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Indacaterol.Approved, Investigational
MometasoneIndacaterol may increase the hypokalemic activities of Mometasone.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Moxifloxacin.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Indacaterol.Approved
NCX 1022Indacaterol may increase the hypokalemic activities of NCX 1022.Investigational
NebivololNebivolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
NefazodoneThe metabolism of Indacaterol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Indacaterol can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Indacaterol can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Indacaterol can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Indacaterol.Withdrawn
NicardipineThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
NiguldipineThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Niguldipine.Experimental
NilotinibIndacaterol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Indacaterol can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Indacaterol can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Indacaterol can be increased when it is combined with Nitrendipine.Approved, Investigational
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indacaterol.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Indacaterol.Withdrawn
OfloxacinIndacaterol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
OlaparibThe metabolism of Indacaterol can be decreased when combined with Olaparib.Approved
Oleoyl-estroneIndacaterol may increase the hypokalemic activities of Oleoyl-estrone.Investigational
OmeprazoleThe serum concentration of Indacaterol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Indacaterol.Investigational
OsimertinibThe serum concentration of Indacaterol can be increased when it is combined with Osimertinib.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Indacaterol.Approved
PalbociclibThe serum concentration of Indacaterol can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneIndacaterol may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatIndacaterol may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParamethasoneIndacaterol may increase the hypokalemic activities of Paramethasone.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Indacaterol.Approved
ParoxetineThe serum concentration of Indacaterol can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibIndacaterol may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
PentamidineIndacaterol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentobarbitalThe metabolism of Indacaterol can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerflutrenIndacaterol may increase the QTc-prolonging activities of Perflutren.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Indacaterol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Indacaterol.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Pheniramine.Approved
PhenobarbitalThe serum concentration of Indacaterol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may decrease the vasoconstricting activities of Indacaterol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Indacaterol.Withdrawn
PhentolaminePhentolamine may decrease the vasoconstricting activities of Indacaterol.Approved
PhenytoinThe metabolism of Indacaterol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideIndacaterol may increase the QTc-prolonging activities of Pimozide.Approved
PindololPindolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
PiretanideIndacaterol may increase the hypokalemic activities of Piretanide.Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Indacaterol.Approved
PitolisantThe serum concentration of Indacaterol can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Indacaterol.Withdrawn
PizotifenPizotifen may decrease the vasoconstricting activities of Indacaterol.Approved
PolythiazideIndacaterol may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Indacaterol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneIndacaterol may increase the hypokalemic activities of Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateIndacaterol may increase the hypokalemic activities of Prasterone sulfate.Investigational
PrazosinPrazosin may decrease the vasoconstricting activities of Indacaterol.Approved
PrednicarbateIndacaterol may increase the hypokalemic activities of Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Indacaterol.Approved, Vet Approved
PrednisoneIndacaterol may increase the hypokalemic activities of Prednisone.Approved, Vet Approved
PregnenoloneIndacaterol may increase the hypokalemic activities of Pregnenolone.Approved, Experimental, Investigational
PrimaquineIndacaterol may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Indacaterol can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideIndacaterol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Indacaterol.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Indacaterol.Approved, Investigational
PromazineIndacaterol may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Indacaterol can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Propafenone.Approved
PropericiazinePropericiazine may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Indacaterol.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
PropranololPropranolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indacaterol.Approved
QuetiapineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Quetiapine.Approved
QuinethazoneIndacaterol may increase the hypokalemic activities of Quinethazone.Approved
QuinidineIndacaterol may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineIndacaterol may increase the QTc-prolonging activities of Quinine.Approved
RacepinephrineRacepinephrine may decrease the vasoconstricting activities of Indacaterol.Approved
RanitidineThe serum concentration of Indacaterol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Indacaterol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Indacaterol.Approved
RifabutinThe metabolism of Indacaterol can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Indacaterol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Indacaterol can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneIndacaterol may increase the hypokalemic activities of Rimexolone.Approved
RisperidoneRisperidone may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
RucaparibThe metabolism of Indacaterol can be decreased when combined with Rucaparib.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Indacaterol.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Indacaterol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Indacaterol.Approved
SaquinavirThe metabolism of Indacaterol can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Sarilumab.Approved, Investigational
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Indacaterol.Approved, Investigational, Vet Approved
SildenafilThe metabolism of Indacaterol can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Indacaterol.Approved
SiltuximabThe serum concentration of Indacaterol can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Indacaterol can be increased when it is combined with Simeprevir.Approved
SotalolSotalol may decrease the bronchodilatory activities of Indacaterol.Approved
SpironolactoneThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Spironolactone.Approved
St. John's WortThe serum concentration of Indacaterol can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Indacaterol can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Indacaterol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TamsulosinTamsulosin may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
TelaprevirThe metabolism of Indacaterol can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinIndacaterol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Indacaterol can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Indacaterol.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Terodiline.Experimental
TertatololTertatolol may decrease the bronchodilatory activities of Indacaterol.Experimental
TetrabenazineIndacaterol may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetrandrineThe serum concentration of Indacaterol can be increased when it is combined with Tetrandrine.Experimental
TheophyllineThe risk or severity of adverse effects can be increased when Theophylline is combined with Indacaterol.Approved
ThioproperazineThioproperazine may decrease the vasoconstricting activities of Indacaterol.Approved
ThioridazineIndacaterol may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Indacaterol.Approved, Investigational
TiclopidineThe metabolism of Indacaterol can be decreased when combined with Ticlopidine.Approved
TimololTimolol may decrease the bronchodilatory activities of Indacaterol.Approved
TixocortolIndacaterol may increase the hypokalemic activities of Tixocortol.Approved, Withdrawn
TocilizumabThe serum concentration of Indacaterol can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may decrease the vasoconstricting activities of Indacaterol.Approved, Vet Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Indacaterol.Approved
TorasemideIndacaterol may increase the hypokalemic activities of Torasemide.Approved
ToremifeneIndacaterol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.Approved, Investigational
TrazodoneTrazodone may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
TriamcinoloneIndacaterol may increase the hypokalemic activities of Triamcinolone.Approved, Vet Approved
TrichlormethiazideIndacaterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may decrease the vasoconstricting activities of Indacaterol.Approved, Investigational
TrimazosinTrimazosin may decrease the vasoconstricting activities of Indacaterol.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indacaterol.Approved
UlobetasolIndacaterol may increase the hypokalemic activities of Ulobetasol.Approved
UrapidilUrapidil may decrease the vasoconstricting activities of Indacaterol.Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Valaciclovir is combined with Indacaterol.Approved, Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Valproic Acid.Approved, Investigational
VandetanibIndacaterol may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Indacaterol.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Indacaterol.Approved
VerapamilThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Verapamil.Approved
VoriconazoleThe metabolism of Indacaterol can be decreased when combined with Voriconazole.Approved, Investigational
ZidovudineThe serum concentration of Indacaterol can be decreased when it is combined with Zidovudine.Approved
ZiprasidoneIndacaterol may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolIndacaterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M: Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007 Mar;29(3):575-81. Epub 2006 Nov 29. [PubMed:17135231]
  2. Kagan M, Dain J, Peng L, Reynolds C: Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos. 2012 Sep;40(9):1712-22. doi: 10.1124/dmd.112.046151. Epub 2012 May 30. [PubMed:22648561]
  3. Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013. [PubMed:23641160]
External Links
Human Metabolome Database
HMDB0015608
KEGG Drug
D09318
PubChem Compound
6918554
PubChem Substance
175426936
ChemSpider
5293751
BindingDB
50318159
ChEBI
68575
ChEMBL
CHEMBL1095777
PharmGKB
PA165958348
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Indacaterol
ATC Codes
R03AL04 — Indacaterol and glycopyrronium bromideR03AC18 — Indacaterol
AHFS Codes
  • 12:12.08.12 — Selective Beta 2-adrenergic Agonists
FDA label
Download (360 KB)
MSDS
Download (479 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAsthma (Part 1) / COPD (Part 2)1
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHepatic Insufficiency1
1, 2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedSupportive CareChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentAsthma Bronchial8
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)8
2CompletedTreatmentPersistent Asthma1
2RecruitingTreatmentAsthma Bronchial1
2, 3CompletedTreatmentAsthma Bronchial1
2, 3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Lung Diseases, Obstructive / Pulmonary Disease, Chronic Obstructive2
3CompletedTreatmentAsthma Bronchial2
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)32
3CompletedTreatmentChronic Obstructive Pulmonary Disease: COPD1
3CompletedTreatmentPatients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive1
3RecruitingTreatmentCOPD (Chronic Obstructive Pulmonary Disease)1
3RecruitingTreatmentHeart Failure, Unspecified1
4CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Hyperinflation / Right Cardiac Failure1
4CompletedTreatmentAsthma Bronchial2
4CompletedTreatmentChronic Lung Diseases / Chronic Obstructive Pulmonary Disease (COPD) / Dyspnea / Hypoxemia / Tachycardia1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)11
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
4Not Yet RecruitingNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
4Not Yet RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)3
4WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD)2
Not AvailableCompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailablePulmonary Disease, Chronic Obstructive1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral; Respiratory (inhalation)75 ug/1
CapsuleRespiratory (inhalation)75 mcg
CapsuleRespiratory (inhalation)150 μg
CapsuleRespiratory (inhalation)300 μg
CapsuleRespiratory (inhalation)
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6878721No2000-10-102020-10-10Us
US8067437No2000-06-022020-06-02Us
US8658673No2000-06-022020-06-02Us
US8796307No2000-06-022020-06-02Us
US8479730No2008-10-112028-10-11Us
US7229607No2001-04-092021-04-09Us
US7820694No2000-06-022020-06-02Us
US8029768No2001-04-092021-04-09Us
US8283362No2000-06-022020-06-02Us
US7736670No2001-06-272021-06-27Us
US8435567No2001-06-272021-06-27Us
US8303991No2001-06-272021-06-27Us
US8956661No2001-06-272021-06-27Us
US8580306No2001-06-272021-06-27Us
US6582678No1998-04-242018-04-24Us
US8182838No2008-10-202028-10-20Us
US6521260No1996-01-312016-01-31Us
US8048451No2001-06-272021-06-27Us
US9931304No2001-06-272021-06-27Us
US9962338No2001-06-272021-06-27Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)195-202°C with decompositionNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00798 mg/mLALOGPS
logP3.31ALOGPS
logP3.26ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)8.51ChemAxon
pKa (Strongest Basic)9.71ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.59 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity118.1 m3·mol-1ChemAxon
Polarizability44.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9963
Blood Brain Barrier+0.5
Caco-2 permeable-0.6288
P-glycoprotein substrateSubstrate0.6953
P-glycoprotein inhibitor INon-inhibitor0.9284
P-glycoprotein inhibitor IINon-inhibitor0.9178
Renal organic cation transporterNon-inhibitor0.8838
CYP450 2C9 substrateNon-substrate0.8148
CYP450 2D6 substrateNon-substrate0.6907
CYP450 3A4 substrateSubstrate0.5896
CYP450 1A2 substrateInhibitor0.553
CYP450 2C9 inhibitorNon-inhibitor0.56
CYP450 2D6 inhibitorNon-inhibitor0.8547
CYP450 2C19 inhibitorNon-inhibitor0.5581
CYP450 3A4 inhibitorNon-inhibitor0.6546
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5888
Ames testNon AMES toxic0.7577
CarcinogenicityNon-carcinogens0.8559
BiodegradationNot ready biodegradable0.9856
Rat acute toxicity2.6531 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9657
hERG inhibition (predictor II)Inhibitor0.6406
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hydroxyquinolones. These are compounds containing a quinoline moiety bearing a hydroxyl group and a ketone. Quinoline or benzo[b]pyridine is a bicyclic compound that consists of benzene fused to a pyridine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinolones and derivatives
Direct Parent
Hydroxyquinolones
Alternative Parents
8-hydroxyquinolines / Hydroxyquinolines / Hydroquinolones / Hydroquinolines / Indanes / 1-hydroxy-2-unsubstituted benzenoids / Pyridinones / Aralkylamines / Heteroaromatic compounds / 1,2-aminoalcohols
show 8 more
Substituents
Hydroxyquinolone / Dihydroquinolone / Hydroxyquinoline / 8-hydroxyquinoline / Dihydroquinoline / Indane / 1-hydroxy-2-unsubstituted benzenoid / Pyridinone / Aralkylamine / Benzenoid
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
secondary alcohol, secondary amino compound, indanes, quinolone, monohydroxyquinoline (CHEBI:68575)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Cazzola M, Matera MG, Lotvall J: Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005 Jul;14(7):775-83. [PubMed:16022567]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on October 21, 2007 16:23 / Updated on August 15, 2018 09:52